By Maria Cheng | AP Medical Writer
Vous n'êtes pas connecté
Britain's drug regulator authorized the Alzheimer's drug Leqembi on Thursday, saying it's the first medicine to show some impact in slowing the progression of the neurodegenerative disease.
By Maria Cheng | AP Medical Writer
THURSDAY, Sept. 11, 2024 -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been...
Targeting the key players that help your body regulate metabolism could reverse disease progression, including cognitive decline related to...
Targeting the key players that help your body regulate metabolism could reverse disease progression, including cognitive decline related to...
A study by researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's...
LONDON (AP) — U.K. Prime Minister Keir Starmer’s government said Monday that it’s suspending exports of some weapons to Israel because they...
LONDON (AP) — U.K. Prime Minister Keir Starmer’s government said Monday that it’s suspending exports of some weapons to Israel because they...
Alzheimer’s disease is one of the leading causes of memory loss and confusion in older people worldwide. It is also the most common type of brain...
Former ECB head gives his diagnosis but European Union likely won’t agree to take its medicine
The FDA has approved an updated covid shot for everyone 6 months old and up, which renews a now-annual quandary for Americans: Get the shot now, with...